|
gptkbp:instanceOf
|
gptkb:antibiotic
immunosuppressant drug
mTOR inhibitor
|
|
gptkbp:administeredBy
|
oral route
|
|
gptkbp:affects
|
cell proliferation
cell growth
autophagy
|
|
gptkbp:approvedBy
|
gptkb:FDA
renal transplant rejection
|
|
gptkbp:ATCCode
|
L04AA10
|
|
gptkbp:bioavailability
|
14% (oral)
|
|
gptkbp:brand
|
gptkb:Sirolimus
|
|
gptkbp:CASNumber
|
53123-88-9
|
|
gptkbp:category
|
antifungal agents
antineoplastic agents
immunosuppressive agents
|
|
gptkbp:chemicalFormula
|
C51H79NO13
|
|
gptkbp:consequence
|
extends lifespan in model organisms
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to rapamycin
|
|
gptkbp:discoveredBy
|
gptkb:Suren_Sehgal
|
|
gptkbp:discoveredIn
|
gptkb:Easter_Island
1972
|
|
gptkbp:eliminatedIn
|
biliary excretion
|
|
gptkbp:halfLife
|
62 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rapamycin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits mTOR pathway
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
914.172 g/mol
|
|
gptkbp:origin
|
gptkb:Streptomyces_hygroscopicus
|
|
gptkbp:proteinBinding
|
92%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
gptkb:DB00877
5284616
|
|
gptkbp:researchInterest
|
gptkb:cancer
aging
neurodegenerative diseases
|
|
gptkbp:sideEffect
|
thrombocytopenia
hyperlipidemia
impaired wound healing
|
|
gptkbp:solubility
|
insoluble in water
soluble in ethanol
soluble in DMSO
|
|
gptkbp:synonym
|
gptkb:sirolimus
gptkb:AY-22989
gptkb:Rapamune
|
|
gptkbp:target
|
gptkb:mTORC1
gptkb:FKBP12
|
|
gptkbp:UNII
|
QF9B6QFS0D
|
|
gptkbp:usedFor
|
prevention of organ transplant rejection
treatment of lymphangioleiomyomatosis
|
|
gptkbp:bfsParent
|
gptkb:PI3K/AKT/mTOR_pathway
gptkb:mTOR_pathway
|
|
gptkbp:bfsLayer
|
5
|